Thursday, March 28th | 18 Adar II 5784

Subscribe
May 23, 2013 12:07 pm
0

GE Banking on Israeli Entrepreneur’s Lifesaving “Watch”

× [contact-form-7 404 "Not Found"]

avatar by Zach Pontz

Oxitone heart device. Photo: Oxitone.com.

An Israeli entrepreneur has developed a possible lifesaving device that GE Healthcare has chosen to be a part of its Start-Up Health Academy Entrepreneurship Program.

Using two optical sensors, and another special high-tech tool, Leon Eisen’s new Oxitone device is the world’s first “watch” that takes minute-by-minute readings of heart rate and oxygen levels in the blood.

Eisen tells ISRAEL21c that about half of the people who die from cardiac or pulmonary arrest would be alive if someone had been there to get them to the hospital in time. Oxitone is made to be worn on the wrist to provide a heads-up for someone to get medical assistance on their own, before it’s too late.

“Oxitone takes the pinch out; it’s worn on the wrist instead of the fingertip to provide continuous, wireless non-stop monitoring while you are walking, eating, sleeping or doing sports,” Eisen says.

Blood-oxygen levels are a critical parameter in monitoring COPD (chronic obstructive pulmonary disease), which can prevent patients from getting enough air into their lungs.

Oxitone non-invasively determines if a cardiac event is imminent by following blood-oxygen levels. It may also help people who suffer from sleep apnea, giving peace of mind to the wearer and their loved ones.

When heart rates change and oxygen levels drop, Oxitone sends alerts to pre-determined locations. It can also be used for long-term care, as physicians can access ongoing records to see how a patient is doing over time.

“My product facilitates an early clinical response for cardiac or pulmonary attack,” Eisen explains. “Because it is continuously monitoring, we can provide an emergency alert. With our device, people will feel better because they understand they are protected. This is the breakthrough.”

Share this Story: Share On Facebook Share On Twitter

Let your voice be heard!

Join the Algemeiner

Algemeiner.com

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.